Curcumin as a great contributor for the treatment and mitigation of colorectal cancer.
Carcinogenesis
Clinical studies
Curcumin
In vitro
In vivo
Pharmacodynamics
Pharmacokinetics
Journal
Experimental gerontology
ISSN: 1873-6815
Titre abrégé: Exp Gerontol
Pays: England
ID NLM: 0047061
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
03
04
2021
revised:
30
05
2021
accepted:
01
06
2021
pubmed:
8
6
2021
medline:
17
8
2021
entrez:
7
6
2021
Statut:
ppublish
Résumé
Cancer is one of the life-taking diseases worldwide and among cancer-related death; colorectal cancer is the third most. Though conventional methods of treatment are available, multidrug resistance and side effects are predominant. Physicians and scientists are working side by side to develop an effective medicament, which is safe and cost-effective. However, most failures are obtained when focused on the clinical perspective. This review mainly brings out the correlation between the curcumin and its use for the mitigation of colorectal cancer, the use of curcumin as a chemotherapeutic agent, chemosensitizer, and in a combination and synergistic approach. The pharmacokinetics and pharmacodynamics properties of curcumin and its formulation approach helps in giving an idea to develop new approaches for the treatment of colorectal cancer using curcumin.
Identifiants
pubmed: 34098006
pii: S0531-5565(21)00220-5
doi: 10.1016/j.exger.2021.111438
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Curcumin
IT942ZTH98
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
111438Informations de copyright
Copyright © 2021. Published by Elsevier Inc.